Literature DB >> 18771560

Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome.

Manfredi Rizzo1, Vincenzo Pernice, Arian Frasheri, Gabriele Di Lorenzo, Giovam Battista Rini, Giatgen A Spinas, Kaspar Berneis.   

Abstract

OBJECTIVE: Small, dense low-density lipoproteins (LDL) are a feature of the metabolic syndrome (MS) but their predictive role still remains to be established. We performed a 2-year follow-up study in 124 subjects with MS (63 +/- 6 years), as defined by the American Heart Association/National Heart, Lung and Blood Institute guidelines, to assess clinical and biochemical predictors of cerebro- and cardio-vascular events. METHODS AND
RESULTS: Beyond traditional cardiovascular risk factors, we measured LDL size and subclasses by gradient gel electrophoresis. Clinical events were registered in the 25% of subjects. At univariate analysis subjects with events had increased prevalence of elevated fasting glucose (P = 0.0117), smoking (P = 0.0015), family history of coronary artery disease (P = 0.0033) and higher levels of total- and LDL-cholesterol (P = 0.0027 and P = 0.0023, respectively); LDL size was lower (P < 0.0001), due to reduced larger subclasses and increased small, dense LDL (all P < 0.0001). At multivariate analysis the following were independent predictors of events (univariate odd ratios were calculated): low HDL-cholesterol (OR 15.4, P = 0.0238), elevated fasting glucose (OR 12.1, P = 0.0102), elevated small, dense LDL (OR 11.7, P = 0.0004), elevated blood pressure (OR 9.2, P = 0.0392), smoking (OR 4.8, P = 0.0054).
CONCLUSIONS: This is the first study that assessed the predictive role of small, dense LDL beyond traditional cardiovascular risk factors in subjects with MS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18771560     DOI: 10.1111/j.1365-2265.2008.03407.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  27 in total

1.  Clinical applications of advanced lipoprotein testing in diabetes mellitus.

Authors:  Danyaal S Moin; Anand Rohatgi
Journal:  Clin Lipidol       Date:  2011-08-01

2.  Associations of ApoAI and ApoB-containing lipoproteins with AngII-induced abdominal aortic aneurysms in mice.

Authors:  Jing Liu; Hong Lu; Deborah A Howatt; Anju Balakrishnan; Jessica J Moorleghen; Mary Sorci-Thomas; Lisa A Cassis; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-04       Impact factor: 8.311

3.  Lipoprint adequately estimates LDL size distribution, but not absolute size, versus polyacrylamide gradient gel electrophoresis.

Authors:  Krista A Varady; Benoît Lamarche
Journal:  Lipids       Date:  2011-09-21       Impact factor: 1.880

4.  Circulating Lp-PLA₂ activity correlates with oxidative stress and cytokines in overweight/obese postmenopausal women not using hormone replacement therapy.

Authors:  Jean Kyung Paik; Minkyung Kim; Minjoo Kim; Yuna Yen; Hyeon Yeong Ahn; Sang-Hyun Lee; Jong Ho Lee
Journal:  Age (Dordr)       Date:  2015

5.  Lipoprotein profile, lipoprotein-associated phospholipase A2 and cardiovascular risk in hemodialysis patients.

Authors:  Roberta Rolla; Andreana De Mauri; Ambra Valsesia; Matteo Vidali; Doriana Chiarinotti; Giorgio Bellomo
Journal:  J Nephrol       Date:  2015-05-14       Impact factor: 3.902

Review 6.  Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials.

Authors:  Hisato Takagi; Masao Niwa; Yusuke Mizuno; Hirotaka Yamamoto; Shin-nosuke Goto; Takuya Umemoto
Journal:  Heart Vessels       Date:  2013-05-05       Impact factor: 2.037

7.  LDL particle heterogeneity, and its association with other established cardiovascular risk factors in a young Indian industrial population.

Authors:  Ramakrishnan Lakshmy; Prabhakaran Dorairaj; Mohamad Tarik; Ruby Gupta; Kolli Srinath Reddy
Journal:  Heart Asia       Date:  2012-10-16

8.  Polycystic ovary syndrome is associated with atherogenic changes in lipoprotein particle number and size independent of body weight.

Authors:  Seema Sidhwani; Bert Scoccia; Shwetha Sunghay; Chantale N Stephens-Archer; Theodore Mazzone; Susan Sam
Journal:  Clin Endocrinol (Oxf)       Date:  2011-07       Impact factor: 3.478

9.  Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes.

Authors:  Naila Rabbani; Lisa Godfrey; Mingzhan Xue; Fozia Shaheen; Michèle Geoffrion; Ross Milne; Paul J Thornalley
Journal:  Diabetes       Date:  2011-05-26       Impact factor: 9.461

Review 10.  Does inflammation determine whether obesity is metabolically healthy or unhealthy? The aging perspective.

Authors:  Iftikhar Alam; Tze Pin Ng; Anis Larbi
Journal:  Mediators Inflamm       Date:  2012-10-04       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.